GNMart

GNMart is a South Korean biotechnology company focused on developing first-in-class therapeutics for neurodegenerative diseases, with a specific emphasis on TDP-43 proteinopathy. The company's lead candidate, GNM-101, is a small molecule designed to inhibit the pathological aggregation of TDP-43, a key driver in the progression of Amyotrophic Lateral Sclerosis (ALS). GNMart is currently advancing GNM-101 through Phase 1 clinical trials, aiming to provide a disease-modifying treatment for a condition with limited therapeutic options. Beyond ALS, the company is leveraging its proprietary screening platform to target other TDP-43-related disorders, including Frontotemporal Dementia and Alzheimer's disease. Founded by experts in protein homeostasis, GNMart combines deep biological insights with efficient drug discovery processes to address high unmet medical needs in neurology.